A randomized prospective comparative study of efficacy of asenapine, iloperidone and zotepine in patients with psychosis
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20162842Keywords:
Atypical antipsychotics, Efficacy, Brief psychiatric rating scale, Psychosis, SchizophreniaAbstract
Background: Antipsychotic drugs constitute the mainstay in the treatment of schizophrenia and other psychotic disorders. For these medications to be maximally beneficial, they must be efficacious, with an acceptable side effect profile and be taken as prescribed. The objective of the study was to compare the efficacy of iloperidone, asenapine and zotepinein subjects with psychotic disorders.
Methods: Randomized prospective study was conducted in the Department of Psychiatry of a tertiary care hospital, at Mysore, India. Sixty Patients who met the criteria for acute psychosis and schizophrenia according to ICD 10 were recruited. Atypical antipsychotics-asenapine, iloperidone and zotepine were administered and their efficacy was monitored by brief psychiatric rating scale (BPRS), which was administered on day one, week 1, week 3 and week 6.
Results: Out of 60 recruited subjects 31 (51.7%) completed all four visits of the study. Iloperidone and asenapine showed significant improvement in efficacy than zotepine at week 6. Among the total dropouts 55.2% subjects didn’t come for follow-up and 44.8% were dropped due to development of side effects.
Conclusions: In patients with acute psychosis and schizophrenia, iloperidone appears more effective and tolerated than the other two. Asenapine was effective but less tolerated and zotepine was less efficacious and produced poor response. Asenapine and zotepine have more dropouts and showed few uncommon extrapyramidal side effects.
References
Cetin M. Asenapine: a novel hope in the treatment of manic and mixed episodes of bipolar I disorder. Bulletin of Clinical Psychopharmacology. 2013;23(1):99-106.
Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: anovel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
Food and Drug Administration. FDA approves Fanapt to treat schizophrenia. Availabe at www.fda.gov/ News Events/newsroom/ Press Announcements/ ucm149578. Accessed on 3 November 2010.
Kalkman HO, Feuerbach D, Lotscher E. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003;73:1151-9.
Ram JB, Venugopal J. Tolerability of zotepine in Indian patients: preliminary experience. Ind Psychiatry J. 2010;19(2):130-1.
Subramamiam S, Rummel KC, Hunter H, Schmid F, Schwarz S, Kissling W et al. Zotepine versus other atypical antipsychotics for schizophrenia (review). The Cochrane Collaboration. 2012.
Butler A, Wighton CP, Welch JA, Tweed BD, Byrom CR. The efficacy of zotepine in schizophrenia: a meta-analysis of BPRS and improvement scale scores. Int J Psych Clin Pract. 2000;4:19-27.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Report. 1962;10:799-812.
Intyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panaqides. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673-86.
Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492-500.
Citrome L. Iloperidone: a clinical review. J Clin Psychiatry. 2011;72(1):19-23.
Cutler AJ, Kalali AH, Weidett PJ, Hamilton J, Wolfgang CD. Four-week double blind, placebo and ziprasidone contolled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28:20-8.
Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2):4-11.
Petit M, Raniwalla J, Tweed J. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull. 1996;32:81-7.
Briken P, Nika E, Moritz S, Haasen C, Perro C, Yagdiran O et al. Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophrenia Research. 2002;57:311-3.
